Hope for transplant patients after world-first Queensland immunotherapy trial

Published: Comments:
Community Health & Wellness Science & Research

The Coordinator of QIMR Berghofer’s Centre for Immunotherapy and Vaccine Development, Professor Rajiv Khanna.

Organ transplant patients who face a lifetime of medication to ward off viral infection – or the potentially deadly threat of drug-resistant infection – may have new hope following a world-first clinical trial that uses a patient’s own immune cells as the treatment.

The immunotherapy treatment involved taking blood from patients, effectively training their killer T (immune) cells to destroy the cytomegalovirus (CMV) and reinfusing the cells into sick patients.

QIMR Berghofer Medical Research Institute’s world-leading immunologist, Professor Rajiv Khanna, led the clinical trial, which treated 13 organ transplant patients with a potentially life-threatening cytomegalovirus infection using their own immune cells.

The Phase 1 clinical trial started in 2014 in conjunction with Associate Professor Scott Campbell at Brisbane’s Princess Alexandra Hospital and Professor Dan Chambers at Brisbane’s Prince Charles Hospital, as well as doctors at the Royal Adelaide Hospital.

Professor Khanna, who is also the coordinator of QIMR Berghofer’s Centre for Immunotherapy and Vaccine Development, developed the immunotherapy treatment by using killer T (immune) cells from patients and training them to recognise and destroy the virus.

He said the phase 1 clinical trial showed the T cell therapy for existing or drug-resistant cytomegalovirus was safe and had provided a clinical benefit to some patients.

Eleven patients showed improved symptoms following the immunotherapy, and some of those patients were able to reduce or stop taking anti-viral medication altogether.

“The patients we treated were quite sick from the complications caused by cytomegalovirus, which is an infection experienced by some organ transplant recipients,” Professor Khanna said.

Associate Professor Campbell said that typically, a patient who has had an organ transplant received drugs to protect them from cytomegalovirus.

“But taking those drugs long-term means that some patients can develop a drug-resistant strain of the virus, and develop cytomegalovirus-associated complications due to their weakened immune system,” Associate Professor Campbell said.

“The anti-viral drugs designed to prevent and treat cytomegalovirus also have many other unpleasant or dangerous side-effects that can lead to severe illness, and can even make it impossible to continue using the drug.”

Professor Chambers said the killer T cell immunotherapy may in future provide doctors with another option to treat very unwell patients.

“We believe the treatment has potentially saved the lives of some patients,” Professor Chambers said.

Professor Khanna said the group had now developed a new, expanded and improved version of the therapy, and planned to commence a clinical trial next year, in collaboration with several clinical centres around Australia.

He said the new version of the immunotherapy also aimed to treat other viral infections that are common in solid organ transplant patients.

QIMR Berghofer’s Director and CEO, Professor Frank Gannon, said the immunotherapy was produced in-house at the Institute’s cell manufacturing facility, Q-Gen Cell Therapeutics.

“These early results are extremely promising and we hope in future it will provide a new and routine way to treat transplant patients who become sick as a result of cytomegalovirus infection,” he said.

The QIMR Berghofer-led research has been published today in the journal Clinical Infectious Diseases and was made possible with funding from the National Health and Medical Research Council.

The journal article is available online here: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy549/5049442

QIMR Berghofer Medical Research Institute :
PO Royal Brisbane Hospital, Brisbane, QLD, 4029, Brisbane
07 3845 3752
QIMR Berghofer Medical Research Institute
Showing 9 recent articles for this business
Queensland scientists create functioning human muscle in a dish 10 December 2018 | QIMR Berghofer researchers have created functioning miniature human skeletal muscle – a move that will accelerate research into muscle disease and treatments. More information...
Discovery holds promise for a new oesophageal cancer screening test 04 December 2018 | One of Australia’s most deadly cancers could in future be detected earlier, and with a simple blood test, thanks to research from QIMR Berghofer Medical Research Institute. More information...
QIMR Berghofer helps map the genetic makeup of disease-spreading mosquito 22 November 2018 | QIMR Berghofer scientists have helped map the most complete genetic picture of the potentially deadly Aedes aegypti mosquito. More information...
Clinical trial finds new immunotherapy improves MS symptoms 20 November 2018 | A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has found that it improved symptoms and quality of life for the majority of patients. More information...
Born with a taste for coffee or tea 15 November 2018 | If you have a taste for coffee and want to drink a lot of it, you were probably born that way. More information...
World's largest genetic study of cannabis use identifies 35 genes 28 August 2018 | An international team of researchers has conducted the biggest ever study into genetic predisposition for cannabis use and identified 35 genes that influence whether people are likely to ever use the drug. More information...
Hope for transplant patients after world-first Queensland immunotherapy trial 06 July 2018 | Organ transplant patients who face a lifetime of medication to ward off viral infection – or the potentially deadly threat of drug-resistant infection – may have new hope following a world-first clinical trial... More information...
Major study uncovers new breast cancer genes and opens the door for more discoveries 19 June 2018 | An international team of researchers has used a new scientific method to discover at least 12 new genes that influence the risk of developing breast cancer. More information...
Cancer a hit to the heart and the back pocket 11 June 2018 | One quarter of Queenslanders diagnosed with cancer will pay upfront doctors’ fees of more than $20,000 in the first two years, according to a new study shining a light on out-of-pocket costs for survivors. More information...

comments powered by Disqus

All articles submitted by third parties or written by My Sunshine Coast come under our Disclaimer / Terms of Service